论文部分内容阅读
目的:探讨宫颈癌手术前后血清IL-35的差异表达及其表达变化对宫颈癌复发和转移的预测作用。方法:收集2009年1月至2014年1月就诊于本院行宫颈癌手术切除的Ia–IIa期宫颈癌患者73例,同期选择73例本院体检的健康患者(正常对照组),ELISA法检测上述两组以及患者术前、术后血清中IL-35的表达水平,同时根据术后是否复发比较术后复发和稳定组IL-35的含量,分析其与临床预后的关系。结果:与正常对照组比较,IL-35在手术前后患者血清中的表达升高,P<0.05。术后患者血清中的表达(213.79±23.89)pg/m L较术前(398.71±31.09)pg/m L降低,术后复发患者血清IL-35的表达(374.25±27.74)pg/m L较稳定期患者(183.65±34.51)pg/m L明显增高,P<0.05。IL-35高表达的患者的无病生存时间(DFS)为9.115月,总生存时间(OS)为18.031月,较低表达者明显缩短,P均<0.05,Cox分析示IL-35的表达可作为DFS和OS的独立预后因子。结论:手术前后血清IL-35的水平可作为宫颈癌根治术后预测复发和转移的可能生物标志物。
Objective: To investigate the differential expression of serum IL-35 and the predictive value of its expression on the recurrence and metastasis of cervical cancer before and after cervical cancer operation. Methods: A total of 73 patients with stage Ia-IIa cervical cancer who underwent surgical resection of cervical cancer in our hospital from January 2009 to January 2014 were enrolled. A total of 73 healthy subjects (normal control group) The levels of IL-35 in the two groups and in the patients’ preoperative and postoperative serums were detected, and the relapse and postoperative recurrence and stable group IL-35 levels were analyzed. Results: Compared with the normal control group, the expression of IL-35 in serum of patients before and after operation increased (P <0.05). The postoperative serum level of 213.79 ± 23.89 pg / m L was lower than that of preoperative (398.71 ± 31.09) pg / m L, while the serum level of IL-35 was significantly higher in patients with postoperative recurrence (374.25 ± 27.74) pg / m L Patients in stable phase (183.65 ± 34.51) pg / m L were significantly higher, P <0.05. The disease-free survival time (DFS) of patients with high IL-35 expression was 9.15 months, the total survival time (OS) was 18.031 months, the expression of IL-35 was significantly shortened (all P <0.05) As an independent prognostic factor for DFS and OS. Conclusion: The level of serum IL-35 before and after surgery can be used as a potential biomarker for predicting recurrence and metastasis after radical operation of cervical cancer.